Additionally, CD34+CD38- identifiable LSC populations were measured by flow cytometry, and complete LSC elimination was observed in 10/16 (63%) of patients with myelodysplastic syndrome or AML that had a clinical response. This evidence concerns the gene CD34 and acute myeloid leukemia.